Business / Finance

RSS

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

Meridian Bioscience second quarter net sales increases 32% to $41.1 million

Meridian Bioscience, Inc., today reported fiscal 2011 second quarter and six months net sales of $41.1 million and $78.3 million, respectively, increases of 32% and 6%, respectively, from the same periods of the prior fiscal year;

21 Apr 2011

UnitedHealth Group's consolidated first quarter 2011 revenues increased 10% year-over-year

UnitedHealth Group today reported first quarter results, highlighted by accelerated revenue growth from both its UnitedHealthcare and Optum businesses.

21 Apr 2011

Baxter’s first quarter global sales increase 12% to $3.3 billion

Baxter International Inc. today announced strong financial results for the first quarter of 2011, and raised its outlook for full-year 2011.

From Baxter International Inc. 21 Apr 2011

Alexion first quarter non-GAAP net income increases to $56.3 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three months ended March 31, 2011. Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $166.1 million, reflecting steady additions of new patients, compared to $117.6 million for the same period in 2010.

21 Apr 2011

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement granting Hanmi Pharmaceuticals exclusive rights to their lead compound, KX01, for all oncology indications in selected Asian Territories.

21 Apr 2011

LabCorp first quarter revenues increase 14.6% to $1,368.4 million

Laboratory Corporation of America® Holdings today announced results for the quarter ended March 31, 2011. These results include the operations of Genzyme Genetics, which the Company acquired in the fourth quarter of 2010.

21 Apr 2011

Covidien second quarter net sales up 10% to $2.80 billion

Covidien plc today reported results for the second quarter of fiscal 2011 (January - March 2011). Net sales of $2.80 billion increased 10% from the $2.55 billion reported in the second quarter a year ago. Foreign exchange rate movement added approximately two percentage points to the quarterly sales growth rate.

21 Apr 2011

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results.

21 Apr 2011

ICON first quarter net revenue increases 4.6% to $229 million

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2011.

21 Apr 2011

KellBenx secures $2.5 million from initial funding round

KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has secured an initial funding round of $2.5 million from four investors – three biotechnology venture capital groups and one angel investor. The round will finance a clinical trial and laboratory testing of a new, minimally invasive blood test designed to identify risks to pregnancy ranging from pre-term birth to genetic conditions.

21 Apr 2011

BSD Medical sells hyperthermia systems to a U.S. Government medical facility

BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced today that a U.S. Government medical facility has purchased a BSD-500 Hyperthermia System (BSD-500).

21 Apr 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Cancer Centers of North Carolina buys WROS from Wake Radiology

Cancer Centers of North Carolina (CCNC), an affiliate of the United Network of US Oncology and the first practice to offer community-based outpatient cancer care in the Triangle with locations in Raleigh, North Raleigh, Cary, Dunn and Clayton, has purchased Wake Radiology Oncology Services (WROS) from Wake Radiology, the oldest and largest multi-site radiology group in central North Carolina.

21 Apr 2011

Shanghai Pharmaceutical and Pfizer enter MOU to pursue potential business opportunities

Shanghai Pharmaceutical Co. Ltd. and Pfizer Inc. today announced the signing of a memorandum of understanding (MOU) for the companies to jointly pursue potential business opportunities in China.

21 Apr 2011

United Medical Systems expands mobile stereotactic biopsy operations with acquisition of Mobile Biopsy

United Medical Systems, Inc. announces the acquisition of Mobile Biopsy, Inc., a Statesville, North Carolina based company, for an undisclosed cash amount.

21 Apr 2011

Prism Pharmaceuticals to be acquired by Baxter

Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.

From Baxter International Inc. 20 Apr 2011

Aduro raises $19.25 million through Series B equity financing

Aduro BioTech, a clinical-stage immunotherapy company, announced today that it has completed its Series B equity financing from a combination of current investors and Morningside Ventures, bringing the total capital secured in this round to $19.25 million. In addition, Ms. Stephanie O'Brien, who represents Morningside, has joined Aduro's Board of Directors.

20 Apr 2011

St. Jude Medical first quarter net sales increases 9% to $1.376 billion

St. Jude Medical, Inc. today reported sales and net earnings for the first quarter ended April 2, 2011.

20 Apr 2011

bluebird bio announces receipt of additional $30 million in financing

bluebird bio, an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced that the company has secured an additional $30 million in financing.

20 Apr 2011